Zilganersen · Zanvastro

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Alexander Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Alexander Disease

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026FDA action dateFDA PDUFA action date set for zilganersen
US, FDA · Source ↗
22 September 2025Topline resultPivotal study topline
Ionis Pharmaceuticals · Source ↗